Scientists have identified a potential new treatment approach for Hutchinson-Gilford progeria syndrome (HGPS), a progressive genetic disorder that causes rapid and premature aging in children.
The findings in mice, published today in eLife, show that blocking a protein called ICMT can improve the condition of affected cells without reducing cell division and growth. ICMT is involved in modifying the structure of progerin, the mutant protein that causes HGPS.
These results suggest that ICMT could be a useful drug target to treat HGPS, especially as cell division and growth are important for development in children.
HGPS is caused by progerin, a mutant protein which undergoes two types of structural modifications called farnesylation and methylation. Progerin accumulates between the membranes that surround the cell nucleus, leading to damage that makes cells slow down their growth and die prematurely.
Current treatments for HGPS prevent the farnesylation of progerin, but although these drugs improve some symptoms in patients, they can stop cells from multiplying. Previous experiments have suggested that inactivating the gene for the protein ICMT, which normally causes the methylation of progerin, can also improve key symptoms while avoiding the effects on cell growth and division. However, these benefits have only been demonstrated in HGPS cells outside the body and in mice with a mimic of the disease.
"Previous research has raised the possibility that inhibiting ICMT activity could be an effective therapeutic strategy," explains first author Xue Chen, a PhD student at the Department of Biosciences and Nutrition, Karolinska Institutet, Sweden. "We wanted to determine if these therapeutic benefits would be seen in living mice with HGPS and whether we could use existing drugs to safely reproduce the effects of genetic inactivation on a cellular level."
To do this, the researchers used mice with HGPS that produced progerin and inactivated the ICMT gene, observing how it affected their health. They found that the mice which lacked ICMT survived significantly longer, and had higher body weights, compared to unmodified mice with progeria. They also had larger skeletal muscle fibres, and the muscle cells around their aorta - the large artery in the heart necessary for transporting oxygen-rich blood - resembled those of healthy mice. This result is particularly important as cardiovascular problems are the main cause of mortality in children with HGPS.
The team next treated HGPS cells and the HGPS-mimicking cells from mice with a synthetic chemical called C75 that strongly inhibited the ICMT protein. This treatment delayed the deterioration of the cells and stimulated cell division and growth. Importantly, when applied to healthy human cells and mouse cells that lacked the target ICMT protein, C75 had no significant unintended effects, meaning that it has good specificity for HGPS.
"We hope these findings will further incentivise the development of efficacious compounds targeting ICMT," says Mohamed Ibrahim at Sahlgrenska Center for Cancer Research, University of Gothenburg. "This approach would also likely lack the detrimental properties of current protocols treating already frail children with drugs originally developed to treat cancer."
Next, the team studied where the progerin protein accumulates in cells treated with C75. They found that progerin accumulates inside the centre of the cell - the cell nucleus. This suggests that blocking the methylation of progerin by ICMT redirects the proteins and reduces their ability to cause damage.
"Our study has taken important steps in validating ICMT as a potential drug target that could provide advantages over existing treatments for children with this fatal condition," concludes senior author Martin Bergo, Professor at the Department of Biosciences and Nutrition, Karolinska Institutet. "Further studies are now needed to find compounds that can target ICMT in living organisms, not just in cells."
###
Reference
The paper 'A small-molecule ICMT inhibitor delays senescence of Hutchinson-Gilford progeria syndrome cells' can be freely accessed online at https://doi.org/10.7554/eLife.63284. Contents, including text, figures and data, are free to reuse under a CC BY 4.0 license.
This study has been published as part of eLife's special issue on aging, geroscience and longevity. To view the special issue, see https://elifesciences.org/collections/6d673315/aging-geroscience-and-longevity-a-special-issue.
Media contact
Emily Packer,
Media Relations Manager
eLife
e.packer@elifesciences.org
01223 855373
About eLife
eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Cell Biology, while exploring creative new ways to improve how research is assessed and published. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
To read the latest Cell Biology research published in eLife, visit https://elifesciences.org/subjects/cell-biology.